eLetters

234 e-Letters

  • Re: Chronic respiratory failure
    Gerben P Bootsma

    Dear Editor

    The recent case report from Smyth and Riley[1] describes nicely an extremely uncommon chronic respiratory failure due to hypoventilation secondary to brainstem stroke, and documents a new treatment option with medroxyprogesterone acetate.

    We recently saw two patients also with central hypoventilation resulting in chronic type II respiratory failure and treated both with, among other things, me...

    Show More
  • See top of letter
    John H. Lange

    Dear Editor

    Endotoxin: it’s activity in atopy and asthma is not the only controversial issue – does it play a role in prevention of lung cancer in some occupational populations

    The paper Does environmental endotoxin exposure prevent asthma? by Douwes et al. provides an interesting overview of how endotoxin may interact in atopy and asthma. This paper discusses issues as to whether endotoxin pl...

    Show More
  • Marginal benefits of adding formoterol
    Brian J Lipworth

    Dear Editor

    Price and colleages conclude that adding formoterol confers a therapeutic advantage to inhaled steroid in patients with mild to moderate asthma. For the 6 month follow up in part 2 of the study, for the secondary outcome of mild asthma exacerbations,the frequency differed by 2.5 per patient per 6 months ,while for poorly controlled asthma days the difference was 4.2 days per patient per 6 months.

    T...

    Show More
  • Reply to Fowler: Clinical relevance of AMP challenge in asthma
    Riccardo Polosa

    Dear Editor

    We thank Dr Fowler for allowing us to expand further on the subject matter of AMP provocation clinical relevance. Could AMP be the preferred challenge stimulus for monitoring treatment requirements in asthma and to establish the appropriate dose of inhaled GCS needed to control airway inflammation? Although the available evidence clearly indicates that AMP challenge has a selective ability to probe cha...

    Show More
  • DOT for all patients with smear-positive pulmonary TB in London?
    RD Barker

    Dear Editor

    Supervised drug-taking is frequently seen as the answer to rising levels of tuberculosis. Djuretic et al. advocate directly observed therapy (DOT) for all patients with smear-positive pulmonary tuberculosis in London.[1] At first sight, the experience of instituting DOT in New York City appears especially impressive, with a 21 % reduction in case rates 2 and 39 % decrease in drug-resistant isolates....

    Show More
  • Re: Sampling in tuberculosis RFLP clustering analyses
    Helen Maguire

    Dear Editor

    Paynter and Coker have made an important point about the extent to which clustering depends upon sample coverage. We believe that this is valid, but strictly correct only in the situation where a representative (e.g. random) sample of the population have been studied. In our study we included 2490 isolates with linked demographic information. This is 77 % of the total of 3260 culture-confirmed cases...

    Show More
  • Neutrophil involvement in mild asthma.
    David W Reid

    Dear Editor

    We wholeheartedly welcome the article by Douwes et al. and it’s accompanying editorial by O’Donnell and Frew.[1,2] The review highlights the heterogeneity of airway inflammation in 'asthma' and especially the potential role of the neutrophil in a substantial proportion of patients. The authors use the term 'non-eosinophilic asthma' to categorise this disease entity and they state that other manif...

    Show More
  • Sampling in tuberculosis RFLP clustering analyses
    Stuart J Paynter

    Dear Editor

    Maguire et al.[1] estimated recently in the journal that the rate of recent transmission of M tuberculosis in London was 14.4 % between 1995 and 1997. Estimation of this parameter is an important contribution to the understanding of transmission dynamics of tuberculosis in the capital and should assist policy-makers in developing responses to enhance control. We suggest, however, that if this estim...

    Show More
  • Mechanism of airflow obstruction in PPH
    Tarek Saba

    Dear Editor

    I read with interest the paper by Meyer et al about the increased incidence of peripheral airflow obstruction in 171 patients with PPH when compared to 64 age and sex matched controls. [1]

    The authors speculate on possible explanations for this finding. They provide three main theories, all of which are plausible. First, that increased production of cytokines and growth mediators in...

    Show More
  • AMP challenge in asthma
    Stephen J Fowler

    Dear Editor

    Dr Polosa and colleagues provided an informative review of the mechanisms and clinical application of bronchial challenge with adenosine monophosphate (AMP) in asthma and COPD.[1] I would however contest their proposal that AMP may be the preferred challenge stimulus for monitoring treatment efficacy, as well as disease progression and severity when compared with direct agents such as methacholine, and a...

    Show More

Pages